同仁堂公告称，其分支机构同仁堂制药厂收到加拿大卫生部核准签发的《产品许可证（三类）》，产品 参苓白术散获加拿大产品注册。该产品为散剂，用于缓解脾胃虚弱等症状。截至公告日，该产品研发投 入累计约229万元。不过，产品若在加拿大销售，还需完成生产场地的加拿大生产质量体系认证等审 批，存在不确定性，且获批事宜对公司近期经营业绩无重大影响。 ...

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has successfully negotiated to include its proprietary product, Yao Xue Qu Feng Zhi Tong Granules, in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, which is expected to positively impact the product's market promotion and sales scale [1] Group 1 - The product Yao Xue Qu Feng Zhi Tong Granules is an innovative traditional Chinese medicine developed by the company [1] - The inclusion in the 2025 Medical Insurance Catalog will enhance the product's market access and sales potential [1] - The company anticipates a positive impact on future operating performance and market share, although no significant short-term effects on operating results are expected [1]

12月5日至6日，2025心血管健康大会在北京国家会议中心隆重举行，大会吸引近2万人参会，来自国内外的心血管领域权威专家与学者，围绕守护民众心 血管健康展开深度交流。会上，津药达仁堂参与的国家科技重大专项——"速效救心丸治疗气滞血瘀型择期PCI相关冠脉微血管疾病的多中心随机对照研 究"重磅启动。 国家中医药管理局科技司相关负责人、中国科学院陈可冀院士、中国工程院张伯礼院士、复旦大学附属中山医院葛均波院士、北京中医药大学东直门医院 王勇院长、王显教授、北京大学第一医院霍勇教授、北京大学韩晶岩教授、河南中医药大学第一附属医院朱明军教授等多位专家、领导出席，52万人次线 上同步观看，共同见证这一重要时刻。 直击临床困境，破解心肌灌注"最后一公里"难题。冠状动脉微血管疾病是当前冠心病治疗的关键难点。数据显示，即使通过PCI手术成功开通堵塞的大血 管，仍有超过30%的患者因微循环障碍导致心肌组织灌注不足，严重影响术后恢复和生活质量。以心脑血管病为主的四大慢病重大专项是落实《"健康中 国2030"规划纲要》的重要举措。在葛均波院士引领下、霍勇教授、王显教授、朱明军教授、毛静远教授等诸多心血管领域专家共同努力，深耕冠状动脉 ...

中国经济网北京12月8日讯 A股三大指数集体上涨，截至收盘，上证指数报3924.08点，涨幅0.54%，成交额8394.39 亿元；深证成指报13329.99点，涨幅1.39%，成交额11972.07亿元；创业板指报3190.27点，涨幅2.60%，成交额5818.21亿 元。 | 序号 | 板块 | 涨跌幅(%)▼ | 总成交量(万手) ▼ | 总成交额(亿元) * | 净流入(亿元) ▼ | 上涨家数 | 下跌家数 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 通信设备 | 3.55 | 2854.92 | 1481.20 | 84.94 | 80 | 7 | | 2 | 脂源等層 | 3.27 | 382.79 | 174.80 | 20.35 | 13 | 0 | | 3 | 其他电子 | 3.14 | 673.21 | 263.57 | 20.09 | 32 | 2 | | 4 | 元件 | 3.02 | 1394.08 | 601.08 | 53.04 | 56 | 4 | | 5 | 未含体 | 2.39 | 2201.55 ...

创新中药头部企业以岭药业再有一款新药通过谈判，被纳入国家医保目录。 近日，国家医保局公布了《国家基本医疗保险、生育保险和工商保险药品目录(2025年)》，以岭药业独 家品种芪防鼻通片位列其中，成为新进目录的中成药。 以岭药业董事长吴相君在2025创新药高质量发展大会上发言时指出，治疗过敏性鼻炎的芪防鼻通片获批 纳入医保目录，成为以岭药业第5个通过国家医保谈判的创新中药。这既是对企业创新价值的认可，更 是企业沉甸甸的责任。以岭药业将充分发挥理论创新和研发生产优势，全力做好药品供应保障。 行业人士表示，今年医保调整，体现出医保部门对创新药"真支持创新、支持真创新、支持差异化创 新"的导向。 今年1月，以岭药业发布公告称，芪防鼻通片新药注册申请获正式批准，注册分类为中药1.1类创新药； 7月，芪防鼻通片通过澳门特别行政区政府药物监督管理局注册审批，成为首个在澳门获批注册的创新 中药。 芪防鼻通片治疗过敏性鼻炎(肺脾两虚证)有效性和安全性的多中心、随机、双盲、安慰剂平行对照的Ⅲ 期临床试验结果在国际SCI期刊《民族药理学》杂志刊发。研究显示，芪防鼻通片能显著改善过敏性鼻 炎患者的鼻部症状、眼部症状和全身症状。在鼻部症 ...

Group 1: National Medical Insurance Directory Inclusion - Heng Rui Medicine has multiple drugs included in the 2025 National Medical Insurance Directory [1] - Xing Qi Eye Medicine has 39 products continuing to be included in the National Medical Insurance Drug Directory [1] - Bei Da Pharmaceutical has four products included in the National Medical Insurance Drug Directory [1] - Junshi Biosciences has added indications for Tuoyi® and included Junshida® in the National Medical Insurance Directory [1] - Zhongsheng Pharmaceutical's innovative drug Angladiwei tablets have been included in the National Medical Insurance Directory through negotiation [1] - Yiling Pharmaceutical's subsidiary has its exclusive product Qifang Nasal Tablets included in the National Medical Insurance Directory, totaling 12 exclusive patented traditional Chinese medicine products [1] - Aosaikang's product Liratinib tablets (Aoyi Xin®) has been included in the 2025 National Medical Insurance Directory [1] - Kanghong Pharmaceutical's product Kangbai Xip eye injection (Langmu) has been included in the 2025 National Medical Insurance Directory [1] - Dongcheng Pharmaceutical's Technetium-99m injection has been included in the medical insurance directory; its subsidiary has received clinical trial approval for 177Lu-LNC1009 injection [1] - Micron Biomedical's Sidabena tablets have been included in the National Medical Insurance Directory for regular Class B management [1] - Haichuang Pharmaceutical's Deuteroenzalutamide soft capsules have been included in the National Medical Insurance Directory for the first time [1] - Huadong Medicine's subsidiary products and cooperative products have been included in the National Medical Insurance and commercial insurance innovative drug directory [1] - Aidi Pharmaceutical's two anti-HIV innovative drugs continue to be included in the National Medical Insurance Directory through a simplified renewal process [1] Group 2: Corporate Developments - Hengyin Technology has signed a cooperation agreement with Muxi Co., focusing on the domestic GPU scenario [1] - Jia Jian Co. is planning a change in control, with stock resuming trading on December 8 [2] - Gu Ao Technology's actual controller is planning a change in control, leading to stock suspension [2] Group 3: Financial Performance - Tianbang Food reported a commodity pig sales revenue of 654 million yuan in November, a month-on-month increase of 7.66% [3] - Tian Ci Materials' controlling shareholder has committed not to reduce company shares [3]

2025.12.07 本文字数：1371，阅读时长大约3分钟 作者 |第一财经钱童心 近日，第一财经记者注意到网上有不少消费者抱怨为了买老字号中药品牌"北京同仁堂"的产品，在网上选了又选，但最后还是买到了"假的同仁堂"—— 没有"双龙标"。 为此，记者从互联网电商平台上搜索"北京同仁堂"发现，确实存在多个"北京同仁堂"商标，例如北京同仁堂兴安保健拥有的"内廷上用"相关商标，以及 北京同仁堂（四川）药业拥有的"朕皇"相关商标。 公开信息显示，北京同仁堂兴安保健、北京同仁堂（四川）药业均为北京同仁堂集团的下属公司。2024年8月，同仁堂集团曾发布声明称"从未允许下属 公司使用'同仁堂'商标、字号及任何含有'北京同仁堂''同仁堂'字样的标识，对外开展招商加盟活动，该类合作、加盟、宣传、销售行为均与我公司无 关。"今年9月，该集团又提到其依法享有"同仁堂双龙商标"的注册商标专用权，任何未经授权擅自使用的行为均属于侵权行为。 对此，上海大邦律师事务所合伙人游云庭对第一财经记者表示："北京同仁堂下属公司使用其自有商标，委托生产商或授权第三方生产药品时，虽然号 称使用的是内廷上用，朕皇等商标，但这些产品显著位置均有其公司全 ...

2025.12. 07 本文字数：1371，阅读时长大约3分钟 作者 | 第一财经 钱童心 近日，第一财经记者注意到网上有不少消费者抱怨为了买老字号中药品牌"北京同仁堂"的产品，在 网上选了又选，但最后还是买到了"假的同仁堂"——没有"双龙标"。 对此，上海大邦律师事务所合伙人游云庭对第一财经记者表示："北京同仁堂下属公司使用其自有商 标，委托生产商或授权第三方生产药品时，虽然号称使用的是内廷上用，朕皇等商标，但这些产品显 著位置均有其公司全称，但其中 ' 北京同仁堂 ' 这几个字的字体明显和公司全称里的其他内容不一 致，消费者非常容易就可以发现北京同仁堂的字样，在商标法上，这种属于突出使用，实际上还是对 北京同仁堂进行了商标性使用。" 游云庭分析称，作为上级公司，北京同仁堂虽然对外声称对外没有贴牌，但作为医药领域的公司，不 可能不知道下属公司对外授权时产品包装对于北京同仁堂的使用方式，而这种使用方式，虽然也可以 解释为公司名称权或者字号权，但从消费者认知的角度，依然是在使用北京同仁堂的商标。 "因此，使用'内廷上用'，'朕皇'等商标的产品如果发生质量问题，或者虚假宣传问题，北京同仁堂 公司实际也是负有一定责 ...

游云庭分析称，作为上级公司，北京同仁堂虽然对外声称对外没有贴牌，但作为医药领域的公司，不可能不知道下属公司对外授权时产品包装对于北京同仁 堂的使用方式，而这种使用方式，虽然也可以解释为公司名称权或者字号权，但从消费者认知的角度，依然是在使用北京同仁堂的商标。 "因此，使用'内廷上用'，'朕皇'等商标的产品如果发生质量问题，或者虚假宣传问题，北京同仁堂公司实际也是负有一定责任的。"他向第一财经记者表 示。 近日，第一财经记者注意到网上有不少消费者抱怨为了买老字号中药品牌"北京同仁堂"的产品，在网上选了又选，但最后还是买到了"假的同仁堂"——没 有"双龙标"。 基于上述分析，游云庭认为，如果消费者真正信赖的是北京同仁堂这个商标的，需要在购买之前，查看产品的包装，选择母公司出品的产品，否则就有可能 买到其下级公司授权第三方生产的产品，也就是所谓的"贴牌产品"。 为此，记者从互联网电商平台上搜索"北京同仁堂"发现，确实存在多个"北京同仁堂"商标，例如北京同仁堂兴安保健拥有的"内廷上用"相关商标，以及北京 同仁堂（四川）药业拥有的"朕皇"相关商标。 他进一步分析称，北京同仁堂商标事件的本质是北京同仁堂母公司在维护品牌核 ...

Core Viewpoint - The article discusses the revenue breakdown and pipeline progress of leading cardiovascular device companies for Q3 2025, highlighting growth trends and market dynamics in the cardiovascular sector [11][15][21][27][33][38]. Market Review - The CITIC Medical Index decreased by 0.73%, underperforming the CSI 300 Index by 2.00 percentage points, ranking 22nd among 30 primary industries [7]. - Top-performing stocks included Haiwang Biological, Ruikang Medicine, and Guangdong Wannianqing, while the worst performers were ST Jingfeng and Kangzhi Pharmaceutical [7]. Overall Viewpoint and Investment Themes - **Innovative Drugs**: The domestic innovative drug industry is transitioning from quantity to quality, focusing on differentiated and internationalized pipelines, with a recommendation to pay attention to products that can ultimately generate profits by 2025 [9]. - **Medical Devices**: 1. The bidding volume for imaging equipment has significantly rebounded this year, with ongoing updates in equipment and supportive policies for home medical devices [9]. 2. The domestic market is seeing a notable increase in market share for leading domestic manufacturers due to the implementation of centralized procurement [9]. 3. The orthopedic sector is recovering well post-collection, with new innovations driving incremental revenue [9]. - **Innovation Chain (CXO + Life Science Services)**: There is an expected recovery in overseas investment and a potential bottoming out of domestic investment, indicating a new wave of innovation in the sector [9]. - **Pharmaceutical Industry**: The specialty API sector is anticipated to see cost improvements, leading to a new growth cycle [10]. Company-Specific Insights - **Abbott**: In Q3 2025, Abbott's cardiovascular revenue reached $3.137 billion, with a year-on-year growth of 12.5%. Key growth drivers included heart rhythm management and structural heart disease segments [15]. - **Medtronic**: Medtronic's cardiovascular revenue was $3.436 billion in Q3 2025, growing by 9.3%, with significant contributions from heart rhythm and heart failure segments [21]. - **Boston Scientific**: The company reported cardiovascular revenue of $3.343 billion, a 22.4% increase, driven by the growth of the Watchman and electrophysiology segments [27]. - **Johnson & Johnson**: The cardiovascular segment generated $2.213 billion in Q3 2025, with a 12.6% growth, supported by the acquisition of Shockwave and strong performance in electrophysiology [33]. - **Edwards Lifesciences**: The company achieved cardiovascular revenue of $1.55 billion, a 14.7% increase, with strong growth in transcatheter aortic valve replacement (TAVR) and mitral valve therapies [38]. Pipeline Developments - **Abbott**: The company is advancing its pipeline with new products in heart rhythm management and structural heart disease, including the AVEIR leadless pacemaker and Tendyne transcatheter mitral valve replacement system [16]. - **Medtronic**: The company is focusing on expanding its TAVR system and has received FDA approvals for several new products in the electrophysiology space [22]. - **Boston Scientific**: The company is enhancing its electrophysiology portfolio with the FARAPULSE PFA system, which has received FDA approval for expanded indications [28]. - **Johnson & Johnson**: The company is leveraging its acquisitions to enhance its product offerings in electrophysiology and heart failure management [34]. - **Edwards Lifesciences**: The company is expanding its TAVR and mitral valve product lines, with recent FDA approvals for new therapies [39].